ALXN News and Press, Alexion Pharmaceuticals Inc. From 05/18/21

3 Top Biotech Stocks To Watch In The Stock Market Today Biotech stocks remain on many investors’ radar and for good reasons. Biotech companies are usually more insulated from global events such as the ongoing COVID-19 pandemic and economic uncertainty. Simply put, top biote...

Apellis announced the FDA approval of Empaveli for the treatment of PNH patients. Empaveli's label includes all adults with PNH which was a positive surprise. Empaveli was priced at $458,000 per patient per year, the same price as Ultomiris and a discount to Soliris. Empaveli ...

Form 13F filings show fund managers' top merger arbitrage stocks. Top M&A stocks of the 32 funds I follow. Alexion Pharmaceuticals the top pick. For further details see: Top Merger Stocks Held By Fund Managers, Mid-Q2 2021

John Paulson's Paulson & Co. adds a new stake in Perpetua Resources (PPTA) and exits ViacomCBS (VIAC), which was caught up in the Archegos Capital debacle, according to its latest 13F filing.Boosts stakes in Alexion Pharmaceuticals (ALXN) to 1.4M shares as of March 31, 2021 from 250K shar...

Apellis Pharmaceuticals ([[APLS]] +21.2%) has risen by more than a fifth so far following the FDA approval for EMPAVELI (pegcetacoplan), a targeted C3 therapy for adults with paroxysmal nocturnal hemoglobinuria ((PNH)).EMPAVELI will be a direct competitor to Soliris and Ultomir...

SPAC Business Combination announcements double compared to the previous week. Potential Deal in the Works Domtar Corporation (UFS) agrees to be acquired by Paper Excellence for $3.02 billion. Chevron Corporation (CVX) closes the acquisition of Noble Midstream Partners (NBLX). ...

Are These The Best Biotech Stocks To Buy Now? It is a known fact for investors that biotech stocks are historically volatile in the stock market. Often, the value of the stock is speculative and based on the promise of a new drug or treatment. Until the drug proves viable, recei...

- Accepted abstracts include new Phase 2 safety and tolerability data for CAEL-101 in AL amyloidosis - - Phase 3 studies of CAEL-101 in AL amyloidosis are underway - Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstrac...

– Long-term data evaluate the effectiveness of ULTOMIRIS ® (ravulizumab-cwvz) in reducing the risk of thrombosis in PNH, the primary cause of organ damage and premature death in untreated patients – – Accepted abstracts include new interim Phase 3...

Alexion Pharmaceuticals ([[ALXN]] -0.6%) shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca.The acquisition is expected to close in Q3 2021.Press Release For further details see: Alexion shareholders approve acquisition by ...